No significant difference in neutrophil activation found among three H2RAs

Area of Science:

• Gastroenterology
• Pharmacology
• Immunology

Background:

• Helicobacter pylori eradication is challenging for some patients, necessitating acid-suppressive therapy.
• Previous research suggests ranitidine may inhibit neutrophil activation, unlike famotidine.
• Limited data exists on histamine-2 receptor antagonist effects on neutrophil activation in H. pylori-infected patients.

Purpose of the Study:

• To investigate the impact of three histamine-2 receptor antagonists on neutrophil activation.
• To compare ranitidine, famotidine, and lafutidine effects in H. pylori patients.

Main Methods:

• Prospective, open-label, randomized study of 30 H. pylori-infected patients.
• Patients received ranitidine, famotidine, or lafutidine for 4 weeks.
• Gastric mucosa evaluated for histological findings, myeloperoxidase activity, and IL-8 levels before and after treatment.

Main Results:

• No significant differences in histological findings were observed between pre- and post-treatment groups.
• Myeloperoxidase activity and interleukin-8 levels remained unchanged across all treatment groups.
• The study found no significant effect of the tested histamine-2 receptor antagonists on neutrophil activation markers.

Conclusions:

• Clinical doses of ranitidine, famotidine, and lafutidine can be safely used in H. pylori patients.
• These histamine-2 receptor antagonists do not appear to inhibit neutrophil activation.
• Treatment decisions for H. pylori patients requiring acid suppression can be made without concern for neutrophil activation effects.